Anika Therapeutics (NASDAQ: ANIK) SVP gains shares via RSUs, covers taxes with stock

Rhea-AI Filing Summary

Anika Therapeutics SVP, CAO & Treasurer Ian McLeod reported compensation-related stock activity, mainly from vesting of prior equity awards. On March 14, 2026, he exercised restricted stock units for 3,774 shares of common stock and received an additional 1,161 shares as a grant or award. On March 15, 2026, he exercised further restricted stock units for 2,658 shares. To cover tax withholding obligations tied to these RSU and PSU vestings, the issuer retained 1,449 shares on March 14 and 781 shares on March 15 at $14.20 per share, which are coded as tax-withholding dispositions rather than open-market sales. Following these transactions, McLeod directly holds 24,107 shares of Anika common stock and 2,659 restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLeod Ian

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CAO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		M		3,774	A	(1)	22,518	D
Common Stock	03/14/2026		A		1,161(2)	A	$0	23,679	D
Common Stock	03/14/2026		F		1,449(3)	D	$14.2	22,230	D
Common Stock	03/15/2026		M		2,658	A	(1)	24,888	D
Common Stock	03/15/2026		F		781(4)	D	$14.2	24,107	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/14/2026		M			3,774	(5)	(5)	Common Stock	3,774	$0	7,550	D
Restricted Stock Unit	(1)	03/15/2026		M			2,658	(6)	(6)	Common Stock	2,658	$0	2,659	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. On March 14, 2025, the Reporting Person was granted 3,484 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

3. Reflects an aggregate of 1,449 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

4. Reflects an aggregate of 781 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.

5. On March 14, 2025, the Reporting Person was granted 11,324 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

6. On March 15, 2024, the Reporting Person was granted 7,976 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

	/s/ Ian McLeod	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ian McLeod report in his latest Form 4 for Anika Therapeutics (ANIK)?

Ian McLeod reported vesting and exercises of restricted stock units and performance-based RSUs, plus related tax-withholding share dispositions. These transactions reflect equity compensation events, not open-market buying or selling of Anika Therapeutics common stock, and update his direct ownership position.

How many Anika Therapeutics shares did Ian McLeod acquire through RSU exercises and grants?

Ian McLeod acquired 3,774 Anika common shares from RSU exercises on March 14, 2026, 2,658 shares from RSU exercises on March 15, 2026, and 1,161 additional shares as a grant or award, all as part of previously granted equity compensation arrangements.

How many Anika Therapeutics shares were withheld for Ian McLeod’s taxes in this Form 4?

The issuer retained 1,449 Anika common shares on March 14, 2026, and 781 shares on March 15, 2026, at $14.20 per share to satisfy Ian McLeod’s tax withholding obligations on vested RSUs and performance-based RSUs.

What are Ian McLeod’s Anika Therapeutics share holdings after these transactions?

After the reported transactions, Ian McLeod directly holds 24,107 shares of Anika Therapeutics common stock. He also holds 2,659 restricted stock units, each representing a contingent right to receive one additional share of Anika common stock in the future, subject to vesting.

Were there any open-market share purchases or sales by Ian McLeod in this Anika Form 4?

No open-market purchases or sales are reported. The Form 4 shows RSU and PSU vesting, related exercises coded as M, an equity grant coded as A, and tax-withholding dispositions coded as F, where shares were retained by the issuer to cover tax obligations.

What equity awards underlie the RSU and PSU vesting reported for Ian McLeod at Anika Therapeutics?

The RSU and PSU vesting stems from prior grants, including 3,484 performance-based phantom RSUs granted March 14, 2025, and 11,324 RSUs granted March 14, 2025, plus 7,976 RSUs granted March 15, 2024, each vesting in scheduled installments tied to performance and service.